Back To Search Results

Drug Distribution

Editor: Sairah Sharif Updated: 6/26/2023 9:30:59 PM

Definition/Introduction

Pharmacokinetics is the study of a drug moiety or a compound as it moves through the body after its administration. It involves the processes of drug absorption, bioavailability, clearance, and distribution.[1] Although these processes are theoretically separate, from a practical standpoint in-vivo, they are all inter-connected. After the drug is absorbed from the site of administration, it is distributed to extracellular fluids.[2] High reserves of plasma protein-bound drugs can cause prolonged effects by creating a sustained release mechanism.[3] 

Drug distribution is the disbursement of an unmetabolized drug as it moves through the body’s blood and tissues. The efficacy or toxicity of a drug depends on the distribution in specific tissues and in part explains the lack of correlation between plasma levels and the effects that are seen. Based on the molecular structure, drugs have variable distribution in different types of tissues such as fat, muscle, and brain. Unlike other tissues, the brain and testes are unique, as they contain membrane barriers making a drug significantly less susceptible to distribution.[4] Based on lipid and non-lipid solubility, drugs can be classified as lipophilic or hydrophilic described below. 

Lipophiliic (Fat Soluble)

  • Nonpolar compounds
  • Easily diffuse across lipid bilayers of cell membranes
  • Rx can be administered topically
  • Free diffusion across the blood-brain barrier
  • Biotransformed in the liver 
  • Excreted through the bile duct

Hydrophilic (Water Soluble)

  • Polar compounds
  • Cross lipid bilayers via facilitated transport (passive chemical diffusion across a cell membrane by ion channels or carriers)
  • Eliminated by kidneys

Issues of Concern

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Issues of Concern

Drug distribution is impacted by several factors related to the drug and the body. The drug-related factors include blood and tissue binding proteins, pH, and perfusion. The body-related factors include body water composition, fat composition, diseases (e.g., volume depletion, burns, third spacing).

Clinical Significance

As people age, the overall body water reduces. However, intracellular water remains relatively stable from the first month of life to adulthood. Higher doses of drugs per kilogram weight are required in younger children as they have a higher percentage of water.[5] Lipophilic drugs are more likely to distribute to areas of high lipid density.[6] Body fat varies with age, gender and genetics. Many drugs are bound to plasma proteins, and the most important drug-binding proteins include albumin and globulins. The concentration of these proteins varies with age, nutritional status, and disease.

Understanding drug distribution and pharmacokinetics (PK) is important for all clinicians prescribing medication, along with understanding the fundamentals of protein binding.[7] Only free and unbound drugs will pass from vascular spaces to tissues where a drug-receptor interaction will occur as well as the effect of the drug. Protein binding is not only affected by the concentration of protein but also the pH, metabolic abnormalities (hyperglycemia, uremia), and the presence of other chemicals that will compete for protein binding.

Competition for plasma binding can influence drug effects. For example, Aspirin and Warfarin are known to compete for the same plasma protein binding site. Administering both drugs at the same time will increase the unbound drug, thereby potentiating their effects and potentially lead to bleeding risk.[8] For a drug to be effectively eliminated by the kidney, the drug must be metabolized from a lipophilic molecule into a polar molecule. The liver produces a polar metabolite of the drug, using two unique sets of reactions known as phase I metabolism and phase II metabolism.[9] 

Phase I metabolism involves what is known as the cytochrome P-450 system (CYP enzyme). CYP alters a drug in such a way so that it will be more amenable to combining with polar molecules. These reactions involve basic chemistry principles such as oxidation, reduction, or hydrolysis. Phase II metabolism is the process of adding a polar moiety to the drug, such as sulfate, acetate, or glucuronate. The addition of a polar moiety to a drug makes the drug water-soluble and available for excretion by the kidney. 

Phases of Biotransformation 

  • Phase I reaction: The drug is first transformed into a polar metabolite via oxidation by the cytochrome P-450 system → allows phase II to occur.
  • Phase II reactions: Involves the coupling of the metabolite with glucuronic acid, acetyl groups, sulfates, amino acids, or glutathione.

Types of Drug Kinetics

  • Zero-order kinetics: The rate of metabolism/elimination remains constant and is independent of the concentration of a drug.   
  • First-order kinetics: The rate of metabolism/elimination is directly proportional to the plasma concentration of the drug.

Half-life (T1/2): The time required for a drug's plasma concentration to reach half of its initial value.

  • After 4 half-lives > 90% of the drug is eliminated.

Drug clearance: The measure of the rate of drug elimination → the plasma volume that can be completely cleared of the drug in a given period of time. 

Additionally, uremia not only affects protein binding, but kidneys also play a significant role in drug absorption, distribution, metabolism, and excretion (ADME). Renal dose adjustment is essential in moderate to severe renal failure. Important strategies for managing and drug dosing must be adjusted accordingly, and the risks must be weighed against the benefits.[10] 

Several factors impact drug distribution. These factors include the concentration of drug transporters in blood, pH, perfusion, body water composition, body fat composition, and most certainly disease conditions (e.g., volume depletion, burns, third spacing). The majority of protein binding is relevant only when the drug is more than 90 percent protein bound. In the hypoalbuminemia state, which occurs in malnutrition and inflammation, there is a higher concentration of the unbound drugs. Body composition and metabolic factors also affect drug distribution. For example, during the last trimester of pregnancy, plasma volume expands, so there is an overall diluting effect on plasma proteins. There is also a change in adipose tissue. Additionally, pregnant women are frequently excluded in clinical trials related to drugs.[11] In a critically ill patient, drug distribution also changes due to deranged physiology, protein binding changes, fluid shifts, pH changes, and vascular organ perfusion.[12] Thus it could be useful to monitor drug levels in these conditions if possible.

The cytochrome P-450 system is a family of heme-containing enzymes found in the liver and intestinal tract. There are multiple forms of CYP enzymes. Some drugs can either induce or inhibit specific isoforms of the enzyme, affecting the ADME of a drug. A clinician must be aware of potential drug-drug interactions with CYP enzyme inducers and inhibitors and naturally occurring compounds that can alter the actions of CYP enzyme. Naturally occurring compounds include grapefruit juice, nicotine-containing products, and St. John’s wort.[13][14]

Below is a list of the major drugs that inhibit and induce the cytochrome P-450 system, as well as dugs that are a major substrate of the enzyme: 

CYP1A2

  • Inhibitors: amiodarone, cimetidine, ciprofloxacin, fluvoxamine
  • Inducers: carbamazepine, phenobarbital, rifampin, tobacco
  • Substrates: caffeine, clozapine, theophylline

CYP2C9

  • Inhibitors: amiodarone, fluconazole, fluoxetine, metronidazole, ritonavir, trimethoprim/sulfamethoxazole
  • Inducers: carbamazepine, phenobarbital, phenytoin, rifampin
  • Substrates: carvedilol, celecoxib, glipizide, ibuprofen, irbesartan, losartan

CYP2C19

  • Inhibitors: fluvoxamine, isoniazid, ritonavir
  • Inducers: carbamazepine, phenytoin, rifampin
  • Substrates: omeprazole, phenobarbital, phenytoin

CYP2D6

  • Inhibitors: amiodarone, cimetidine, diphenhydramine, fluoxetine, paroxetine, quinidine, ritonavir, terbinafine
  • Inducers: none
  • Substrates: amitriptyline, carvedilol, codeine, donepezil, haloperidol, metoprolol, paroxetine, risperidone, tramadol

CYP2E1

  • Inhibitors: none
  • Inducers: ethanol, isoniazid, tobacco
  • Substrates: acetaminophen, theophylline, verapamil

CYP3A4 and CYP3A5

  • Inhibitors: clarithromycin, diltiazem, erythromycin, grapefruit juice, itraconazole, ketoconazole, nefazodone*, ritonavir, telithromycin, verapamil 
  • Inducers: carbamazepine, Hypericum perforatum, phenobarbital, phenytoin, rifampin
  • Substrates: alprazolam, amlodipine, atorvastatin, cyclosporine, diazepam, estradiol, simvastatin, sildenafil, verapamil, zolpidem

Below is an additional list of common drug-drug interactions involving the cytochrome P-450 system that clinicians should be aware of: 

Drug: amiodarone 

CYP enzyme: CYP2C9 and CYP3A4 inhibitor                

Drug-Drug Interaction: warfarin       

Metabolizing Enzyme: CYP2C9          

Side Effects: Increased risk of bleeding caused by increased warfarin level.

Drug: carbamazepine, phenobarbital, phenytoin 

CYP enzyme: CYP3A4 inducer             

Drug-Drug Interaction: Ethinyl estradiol-containing contraceptives             

Metabolizing Enzyme: CYP3A4       

Side Effects: Unplanned pregnancy caused by reduced estradiol level.

Drug: clarithromycinerythromycintelithromycin

CYP enzyme: CYP3A4 inhibitor             

Drug-Drug Interaction: simvastatin, verapamil              

Metabolizing Enzyme: CYP3A4          

Side Effects: Myopathy or rhabdomyolysis caused by increased simvastatin level. Hypotension and QT interval prolongation caused by increased verapamil level.

Drug: diltiazemverapamil

CYP enzyme: CYP3A4 inhibitor           

Drug-Drug Interaction: prednisone          

Metabolizing Enzyme: CYP3A4      

Side Effects: Immunosuppression caused by increased prednisolone serum levels.

Drug: fluoxetineparoxetine

CYP enzyme: CYP2D6 inhibitor             

Drug-Drug Interaction: risperidone, tramadol            

Metabolizing Enzyme: CYP2D6   

Side Effects: Increased risk of extrapyramidal adverse effects caused by increased risperidone level.

Drug: Grapefruit juice

CYP enzyme: CYP3A4 inhibitor               

Drug-Drug Interaction: buspirone            

Metabolizing Enzyme: CYP3A4          

Side Effects: Dizziness and serotonin syndrome caused by increased buspirone level.

Drug: metronidazole 

CYP enzyme: CYP2C9 inhibitor            

Drug-Drug Interaction: warfarin               

Metabolizing Enzyme: CYP2C9         

Side Effects: Increased risk of bleeding caused by increased warfarin level.

Drug: terbinafine 

CYP enzyme: CYP2D6 inhibitor          

Drug-Drug Interaction: amitriptyline           

Metabolizing Enzyme: CYP2D6           

Side Effects: Dry mouth, dizziness, and cardiac toxicity caused by a prolonged increase in amitriptyline and nortriptyline.

CYP = cytochrome P-450 

Nursing, Allied Health, and Interprofessional Team Interventions

The interprofessional team and healthcare professionals, including laboratory technologists, pharmacists, nurses, and clinicians, need to all work together to ensure the safety and efficacy of administered drugs. After the clinician chooses the choice and dosage of a particular drug, the pharmacist should verify dosing, report any drug interactions, and take notice of special clinical situations that will influence drug levels and hence efficacy as well as adverse events (e.g., albumin levels, changes in weight, malnutrition, renal and hepatic function). In one study in chronic kidney disease patients, pharmacists identified 5302 drug-related problems and made 3160 recommendations with acceptance rates up to 95%.[15] 

When possible and indicated plasma levels should be followed. Nurses play a critical role in drug administration and alerting the team regarding errors related to medication reconciliation.[16] This team collaboration is an essential part of patient safety in the inpatient and outpatient setting. 

Media


(Click Image to Enlarge)
Pharmacy Calculations: Figure 3: The relationship between pharmacokinetics and pharmacodynamics.
Pharmacy Calculations: Figure 3: The relationship between pharmacokinetics and pharmacodynamics.
Contributed by Piyush Sharma, MDc

References


[1]

Caldwell J, Gardner I, Swales N. An introduction to drug disposition: the basic principles of absorption, distribution, metabolism, and excretion. Toxicologic pathology. 1995 Mar-Apr:23(2):102-14     [PubMed PMID: 7569663]

Level 3 (low-level) evidence

[2]

Feucht C, Patel DR. Principles of pharmacology. Pediatric clinics of North America. 2011 Feb:58(1):11-9, ix. doi: 10.1016/j.pcl.2010.10.005. Epub     [PubMed PMID: 21281845]


[3]

Currie GM. Pharmacology, Part 2: Introduction to Pharmacokinetics. Journal of nuclear medicine technology. 2018 Sep:46(3):221-230. doi: 10.2967/jnmt.117.199638. Epub 2018 May 3     [PubMed PMID: 29724803]


[4]

Dong X. Current Strategies for Brain Drug Delivery. Theranostics. 2018:8(6):1481-1493. doi: 10.7150/thno.21254. Epub 2018 Feb 5     [PubMed PMID: 29556336]


[5]

Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. British journal of clinical pharmacology. 2015 Mar:79(3):395-404     [PubMed PMID: 25855821]


[6]

Mansoor A, Mahabadi N. Volume of Distribution. StatPearls. 2023 Jan:():     [PubMed PMID: 31424864]


[7]

Starkey ES, Sammons HM. Practical pharmacokinetics: what do you really need to know? Archives of disease in childhood. Education and practice edition. 2015 Feb:100(1):37-43. doi: 10.1136/archdischild-2013-304555. Epub 2014 Aug 13     [PubMed PMID: 25122157]


[8]

Grandbois M, Beyer M, Rief M, Clausen-Schaumann H, Gaub HE. How strong is a covalent bond? Science (New York, N.Y.). 1999 Mar 12:283(5408):1727-30     [PubMed PMID: 10073936]


[9]

Bernhardt R. Cytochromes P450 as versatile biocatalysts. Journal of biotechnology. 2006 Jun 25:124(1):128-45     [PubMed PMID: 16516322]

Level 3 (low-level) evidence

[10]

Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Critical care clinics. 2006 Apr:22(2):255-71, vi     [PubMed PMID: 16677999]


[11]

Zhivkova ZD, Mandova T, Doytchinova I. Quantitative Structure - Pharmacokinetics Relationships Analysis of Basic Drugs: Volume of Distribution. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2015:18(3):515-27     [PubMed PMID: 26517139]


[12]

Gonzalez D, Conrado DJ, Theuretzbacher U, Derendorf H. The effect of critical illness on drug distribution. Current pharmaceutical biotechnology. 2011 Dec:12(12):2030-6     [PubMed PMID: 21554214]


[13]

Almazroo OA, Miah MK, Venkataramanan R. Drug Metabolism in the Liver. Clinics in liver disease. 2017 Feb:21(1):1-20. doi: 10.1016/j.cld.2016.08.001. Epub 2016 Oct 15     [PubMed PMID: 27842765]


[14]

Manikandan P, Nagini S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Current drug targets. 2018:19(1):38-54. doi: 10.2174/1389450118666170125144557. Epub     [PubMed PMID: 28124606]


[15]

Al Raiisi F, Stewart D, Fernandez-Llimos F, Salgado TM, Mohamed MF, Cunningham S. Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review. International journal of clinical pharmacy. 2019 Jun:41(3):630-666. doi: 10.1007/s11096-019-00816-4. Epub 2019 Apr 9     [PubMed PMID: 30963447]

Level 1 (high-level) evidence

[16]

Mardani A, Griffiths P, Vaismoradi M. The Role of the Nurse in the Management of Medicines During Transitional Care: A Systematic Review. Journal of multidisciplinary healthcare. 2020:13():1347-1361. doi: 10.2147/JMDH.S276061. Epub 2020 Oct 30     [PubMed PMID: 33154651]

Level 1 (high-level) evidence